Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World’s Premier Cancer Research Forum

Core Insights - Rakovina Therapeutics has had two research abstracts accepted for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, highlighting its advancements in AI-driven oncology therapies [1][2]. Group 1: Research Presentations - The first abstract focuses on a novel brain-penetrant dual ATR-mTOR inhibitor for PTEN-deficient cancers, utilizing the Enki™ generative AI platform to design molecules that inhibit ATR and mTOR, which are critical for the survival of PTEN-deficient cancer cells [3][4]. - The second abstract discusses the development of a lipid nanoparticle formulation of the bifunctional PARP and HDAC inhibitor Kt-3283, which aims to enhance drug delivery and reduce toxicity associated with combination therapies [4][5]. Group 2: Technological Innovations - Rakovina's integration of AI platforms allows for the evaluation of billions of potential compounds at 100 times the speed of traditional methods, significantly accelerating drug discovery [6][7]. - The company collaborates with Variational AI and NanoPalm to optimize drug candidates and enhance delivery mechanisms, showcasing its commitment to innovative cancer treatment solutions [5][7]. Group 3: Market Potential and Pipeline - The oncology market is projected to reach $18 billion annually by 2030, with Rakovina focusing on therapies targeting DNA-repair vulnerabilities present in up to 75% of solid tumors, particularly in hard-to-treat cancers like breast, ovarian, prostate, and brain cancers [8]. - The company is targeting several near-term milestones, including in vivo testing of new lipid nanoparticle formulations and advancing its AI-driven compound refinement programs, which are expected to de-risk its pipeline and support future clinical studies [8].